Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome [Yahoo! Finance]
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners [Yahoo! Finance]
Praxis Precision Medicines to Present at Upcoming December Investor Conferences